AbbVie’s Humira tops ICER’s list of unwarranted price hikes again
ICER says Amgen’s tezepelumab ‘likely to be too expensive’
ICER revises its view of Aduhelm’s price – but not by much
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag
Amgen’s Enbrel heads ICER list of unjustified US price rises
What can Linux and Mozilla teach ICER about how to do drug value assessments?
ICER methods could be illegal in US, claims US think tank
ICER says ‘marginal’ benefits for AbbVie’s new RA drug